Will Liraglutide Make It To WHO's Essential Medicines List?

Application Also Made For Inclusion Of CD19-directed CAR-Ts

Forthcoming review of WHO’s Model List of Essential Medicines is expected to consider glucagon-like peptide 1 receptor agonists such as Novo Nordisk’s liraglutide and also CAR-T therapies, among others. Scrip discusses with experts the prospects of their inclusion and the wider opportunities for industry.

Obesity — Liraglutide, CAR-Ts up for consideration On WHO List • Source: Shutterstock

“Kitchens are dying and eating out or ordering [food] is becoming the norm in many parts of the world,” remarked a pharma industry veteran highlighting changing behavioral patterns that are linked to unhealthy eating, which in turn is among the factors contributing to overweight and obesity.

Call To Include CAR-Ts On WHO List

Researchers from the Department I of Internal Medicine, Evidence-based Medicine Research Group, University Hospital of Cologne and Cochrane Haematology have sought the inclusion of CD19-directed chimeric antigen...

With alarming statistics on the prevalence of obesity and the risk of non-communicable ailments include heart disease, stroke, type 2 diabetes and certain types of cancer, it’s perhaps time to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

28 May 2025

• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.